Skip to main content
Back
INSM logo

Insmed Incorporated

Data quality: 100%
INSM
NASDAQ Healthcare Biotechnology
$143.98
▲ $7.98 (5.87%)
Mkt Cap: 31.04B
Day Range
$141.64 $149.76
52-Week Range
$60.40 $212.75
Volume
3,990,099
50D / 200D Avg
$152.68 / $147.77
Prev Close
$136.00

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -24.3 0.4
P/B 42.0 2.9
ROE % -249.3 3.8
Net Margin % -210.5 3.9
Rev Growth 5Y % 33.9 10.0
D/E 1.0 0.2

Analyst Price Target

Hold
$214.47 +49.0%
Low: $166.00 High: $269.00
Forward EPS
-$2.72
Est. Revenue
1.7 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $11.07
$8.40 – $14.24
6.5 B 6
FY2029 $8.48
$6.44 – $10.91
5.2 B 10
FY2028 $3.97
$0.90 – $7.23
3.9 B 15

Key Takeaways

Revenue grew 33.93% annually over 5 years — strong growth
Negative free cash flow of -967.58M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 32.80%
Capital efficient — spends only 5.37% of revenue on capex

Growth

Revenue Growth (5Y)
33.93%
Revenue (1Y)66.73%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-249.28%
ROIC-58.56%
Net Margin-210.54%
Op. Margin-194.04%

Safety

Debt / Equity
1.04
Current Ratio3.83
Interest Coverage-14.04

Valuation

P/E Ratio
-24.31
P/B Ratio42.00
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 66.73% Revenue Growth (3Y) 40.96%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 33.93% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 606.42M Net Income (TTM) -1.28B
ROE -249.28% ROA -56.38%
Gross Margin 79.41% Operating Margin -194.04%
Net Margin -210.54% Free Cash Flow (TTM) -967.58M
ROIC -58.56% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.04 Current Ratio 3.83
Interest Coverage -14.04 Dividend Yield 0.00%
Valuation
P/E Ratio -24.31 P/B Ratio 42.00
P/S Ratio 51.18 PEG Ratio -1.93
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 31.04B Enterprise Value 31.29B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 606.42M 363.71M 305.21M 245.36M 188.46M
Net Income -1.28B -913.77M -749.57M -481.53M -434.65M
EPS (Diluted) -6.41 -5.57 -5.34 -3.91 -3.88
Gross Profit 481.55M 277.97M 239.64M 190.23M 144.31M
Operating Income -1.18B -878.25M -709.63M -457.32M -375.09M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.26B 2.03B 1.33B 1.66B 1.24B
Total Liabilities 1.53B 1.74B 1.66B 1.57B 833.04M
Shareholders' Equity 738.98M 285.38M -331.92M 87.95M 410.47M
Total Debt 768.16M 1.31B 1.20B 1.18B 612.27M
Cash & Equivalents 510.45M 555.03M 482.37M 1.07B 716.78M
Current Assets 1.79B 1.62B 929.06M 1.27B 837.04M
Current Liabilities 468.87M 297.53M 225.63M 190.24M 135.17M